AlgenScribe Therapeutics
Company Type: Therapeutic development
Main focus: Developing a genome-editing platform to improve human health
Company stage: Pre-clinical
Diseases:
Genome-editing tool: CRISPR-Cas9
Funding stage:
Location: Nice, France
Website: www.algenscribe.com
Pipeline:
Partners: Institut Imagine, The Max Delbrück Center
AlgenScribe Therapeutics is a pre-clinical biotechnology company headquartered in Nice, France. The company is developing a genome-editing platform aimed at improving human health by advancing CRISPR-Cas9 technologies to overcome limitations in targeted applications such as off-target effects. AlgenScribe aims to develop a genome-editing platform that could be applied in therapeutic development, as well as bioproduction, diagnostics, and research tools.